Effects of Clopidogrel on Mortality, Cardiovascular and Bleeding Outcomes in Patients with Chronic Kidney Disease - Data from Taiwan Acute Coronary Syndrome Full Spectrum Registry

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Lin, Tsung Hsien ^a,b   Lai, Wen Ter ^a,b   Hsin, Ho Tsung ^c   Li, Ai Hsien ^c   Wang, Chun Li ^d,e   Kuo, Chi Tai ^d,e   Hwang, Juey Jen ^f   Chiang, Fu Tien ^f   Chang, Shu Chen ^g  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RISK FACTOR; RISK REDUCTION; TAIWAN; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; FEMALE; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RENAL INSUFFICIENCY, CHRONIC; TAIWAN; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84883172585     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071917     Document Type: Article

References (33)

1. Nordlie MA, Wold LE, Kloner RA, (2005) Genetic contributors toward increased risk for ischemic heart disease. J Mol Cell Cardiol. 39(4): 667-79.
2. Taiwan Department of Health. Statistics data. Statistical analysis of 2009 mortality data. Press conference on 2009 mortality data. Available: http://www.doh.gov.tw. Accessed 2011 Jan 19.
3. Budaj A, Eikelboom JW, Mehta SR, Afzal R, Chrolavicius S, et al. (2009) Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J. 30: 655-661.
4. Lindsey JB MS, Pencina M, Stolker JM, Kennedy KF, Rihal C, et al. (2009) Prognostic importance of bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients. JACC Interv. 2: 1074-1082.
5. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, et al. (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 357(20): 2001-15.
6. Melloni C, Alexander KP, Chen AY, Newby LK, Roe MT, et al. (2008) Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes. Am Heart J. 156(2): 209-15.
7. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, et al. (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 375(9731): 2073-81.
8. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, et al. (2010) A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 55(23): 2556-66.
9. USRDS. International comparisons (2009) In: United Stated Renal Data System Annual Data Report. Bethesda, MD: The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease. 344-55.
10. Shyu KG, Wu CJ, Mar GY, Hou Charles JY, Li AH, et al. (2011) Clinical Characteristics, Management and In-Hospital Outcomes of Patients with Acute Coronary Syndrome- Observations from the Taiwan ACS Full Spectrum Registry. Acta Cardiol Sin 2011 27: 135-44.
11. International Epidemiological Association guidelines. Available: http://www.ieaweb.org/index.php?option=com_content&view=article&id=15%3Agood-epidemiological-practice-gep&catid=20%3Agood-epidemiological-practice-gep&Itemid=43&limitstart=1. Accessed 2011 Jan 28.
12. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, et al. (1987) Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 76(1): 142-54.
13. Levey AS, Greene T, Kusek JW, (2000) A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11: A0828.
14. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 39(2Suppl 1): 266.
15. Morel O, El Ghannudi S, Jesel L, Radulescu B, Meyer N, et al. (2011) Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. Am Coll Cardiol. 57(4): 399-408.
16. Keough-Ryan TM, Kiberd BA, Dipchand CS, Cox JL, Rose CL, et al. (2005) Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia. Am J Kid Dis 46: 845-55.
17. Masoudi FA, Plomondon ME, Magid DJ, Sales A, Rumsfeld JS, (2004) Renal insufficiency and mortality from acute coronary syndromes. Am Heart J 147: 623-9.
18. Baber U, Stone GW, Weisz G, Moreno P, Dangas G, et al. (2012) Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. 5(3 Suppl): 53-61.
19. El-Menyar A, Zubaid M, Sulaiman K, Singh R, Al Thani H, et al. (2010) In-hospital major clinical outcomes in patients with chronic renal insufficiency presenting with acute coronary syndrome: data from a Registry of 8176 patients. Mayo Clin Proc. 85(4): 332-40.
20. Undas A, Nycz K, Pastuszczak M, Stompor T, Zmudka K, (2010) The effect of chronic kidney disease on fibrin clot properties in patients with acute coronary syndrome. Blood Coagul Fibrinolysis. 21(6): 522-7.
21. Park SH, Kim W, Park CS, Kang WY, Hwang SH, et al. (2009) A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol. 104: 1292-1295.
22. Angiolillo DJ, Bernardo E, Capodanno D, Vivas D, Sabaté M, et al. (2010) Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol. 55: 1139-1146.
23. Woo JS, Kim W, Lee SR, Jung KH, Kim WS, et al. (2011) Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study. Am Heart J. 162(6): 1018-25.
24. James S, Budaj A, Aylward P, Buck KK, Cannon CP, et al. (2010) Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 122(11): 1056-67.
25. Kaufman JS, Fiore L, Hasbargen JA, O'Connor TZ, Perdriset G, (2000) A pharmacodynamic study of clopidogrel in chronic hemodialysis patients. J Thromb Thrombolysis. 10: 127-131.
26. Cuisset T, Frere C, Moro PJ, Quilici J, Pons C, et al. (2010) Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome. Thromb Res. 126(5): e400-2.
27. Arai T, Kawamura A, Matsubara Y, Yokoyama K, Ikeda Y, et al. (2012) Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents. Heart Vessels. 27(5): 480-5.
28. Keltai M, Tonelli M, Mann JF, Sitkei E, Lewis BS, et al. (2007) Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil. 14(2): 312-8.
29. Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, et al. (2008) The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J. 155(4): 687-93.
30. Htun P, Fateh-Moghadam S, Bischofs C, Banya W, Müller K, et al. (2011) Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol. 22(4): 627-33.
31. Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, et al. (2012) Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 156(6): 445-59.
32. Valente S, Lazzeri C, Chiostri M, Osmanagaj L, Giglioli C, et al. (2011) STEMI patients-the more you bleed, the more you die: a comparison between clssifications. Clin Cardiol. 34(2): 90-6.
33. Suh JW, Mehran R, Claessen BE, Xu K, Baber U, et al. (2011) Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol. 258(17): 1750-6.